PMID- 32648857
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201023
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 56
IP  - 7
DP  - 2020 Jul
TI  - Progress and current status of molecule-targeted therapy and drug resistance in 
      gastric cancer.
PG  - 469-482
LID - 10.1358/dot.2020.56.7.3112071 [doi]
AB  - Gastric cancer is one of the most common malignant tumors in the world. In China, 
      its morbidity and mortality are second only to lung cancer. Chemotherapy combined 
      with targeted therapy brings survival benefits to patients with advanced gastric 
      cancer. Targets for targeted therapy of gastric cancer include human epidermal 
      growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), 
      vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR) 
      and Claudin 18.2 (CLDN 18.2). The main challenge of tumor molecule-targeted drugs 
      is resistance. The main mechanisms of drug resistance include tumor establishment 
      of compensatory signaling pathways, target protein changes, tumor 
      microenvironment changes, tumor heterogeneity and tumor adaptation to targeted 
      drugs. The combined action of multiple drug resistance mechanisms promotes the 
      development of targeted drug resistance. In order to attract the attention of 
      researchers, this paper reviews the mechanisms of drug resistance in gastric 
      cancer-targeted therapy. In addition, the research status of drug resistance in 
      molecule-targeted therapy of gastric cancer is summarized. It is of great 
      clinical significance to explore the drug resistance mechanisms of targeted drugs 
      and reverse drug resistance in gastric cancer. Last, the future development of 
      molecule-targeted therapy is prospected.
CI  - Copyright 2020 Clarivate Analytics.
FAU - Chen, Z
AU  - Chen Z
AD  - Graduate School of Hebei Medical University, Shijiazhuang, China.
AD  - The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China. ynkmchzh@163.com.
FAU - Li, Y
AU  - Li Y
AD  - The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China. li_yong_hbth@126.com.
FAU - Tan, B
AU  - Tan B
AD  - The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Zhao, Q
AU  - Zhao Q
AD  - The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Fan, L
AU  - Fan L
AD  - The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Li, F
AU  - Li F
AD  - Department of Pathology, The Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Zhao, X
AU  - Zhao X
AD  - The Third Department of Surgery, The Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - Drug Delivery Systems
MH  - Drug Resistance
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - *Stomach Neoplasms/drug therapy/genetics
MH  - Tumor Microenvironment
MH  - Vascular Endothelial Growth Factor A
OTO - NOTNLM
OT  - Chemotherapy
OT  - Drug resistance
OT  - Gastric cancer
OT  - Molecule-targeted therapy
OT  - Monoclonal antibodies
OT  - Small-molecule drugs
OT  - Targeted drugs
EDAT- 2020/07/11 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - 3112071 [pii]
AID - 10.1358/dot.2020.56.7.3112071 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2020 Jul;56(7):469-482. doi: 10.1358/dot.2020.56.7.3112071.